Genesis Global Group
Genesis Drug Discovery & Development
GD3

You will now be redirected to the GD3 website

Genesis Drug Discovery & Development is a proud member of Genesis Drug Discovery & Development (GD3), a fully integrated CRO providing services to support drug discovery programs of our clients from target discovery through IND filing and managing Phase I-III clinical trials.

Learn more about GD3
Search

Disease Modeling

Tolerability and Toxicology Services

The evaluation of the tolerability or toxicology of a therapeutic is required for decision-making throughout the program. Tolerability assessments are generally used as preliminary investigations to select appropriate doses for preclinical efficacy experiments and have limited pathological investigation. Non-GLP toxicology assessments can be used to investigate the toxicity induced by a compound to better understand potential concerns around target modulation or to select doses for GLP toxicology studies. GD3 scientists have extensive experience and will work with you to design experiments that are appropriate based on the stage of development of your program, your budget and the questions that you need to answer.

We have experience with many therapeutic modalities and can dose via many different routes of administration, including:

  • Oral gavage
  • Bolus injections:
    • Subcutaneous
    • Intra-peritoneal
    • Intravenous
    • Intra-cardiac
    • Intramuscular
    • Intra-articular
    • Intra-dermal
    • Intra-tracheal
    • Intra-tumoral
  • Osmotic mini-pumps
  • In-diet or water administration